Reduced cross-protective potential of Omicron compared to ancestral SARS-CoV-2 spike vaccines against potentially zoonotic coronaviruses
The COVID-19 pandemic has emphasised the importance of vaccines and preparedness against viral threats crossing species barriers. In response, a worldwide vaccination campaign targeting SARS-CoV-2 was implemented, which provides some cross-protective immunological memory to other coronavirus species with zoonotic potential. Following a vaccination regimen against SARS-CoV-2 spike in a preclinical mouse model, we were able to demonstrate the induction of neutralizing antibodies towards multiple human ACE2 (hACE2)-binding Sarbecovirus spikes. Importantly, compared to vaccines based on the SARS-CoV-2 Reference strain, vaccines based on Omicron spike sequences induced drastically less broadly cross-protective neutralizing antibodies against other hACE2-binding sarbecoviruses. This observation remained true whether the vaccination regimens were based on protein subunit or mRNA / LNP vaccines. Overall, while it may be necessary to update vaccine antigens to combat the evolving SARS-CoV-2 virus for enhanced protection from COVID-19, Reference-based vaccines may be a more valuable tool to protect against novel coronavirus zoonoses.
Authors
- Michael J. McCluskie (ORCID: https://orcid.org/0000-0001-5538-1363)
- Brian Cass
- Bassel Akache (ORCID: https://orcid.org/0000-0002-5377-7193)
- Simon Lord‐Dufour
- Julie Guimond
- Yves Durocher (ORCID: https://orcid.org/0000-0002-2268-4111)
- Tyler M. Renner (ORCID: https://orcid.org/0000-0002-9196-5021)
- Matthew Stuible (ORCID: https://orcid.org/0009-0002-4403-0677)
- Sylvie Perret
Institutions
- National Research Council Canada (CA)
Publication Details
- Journal
- npj Viruses
- Published
- 2024-11-21
- DOI
- https://doi.org/10.1038/s44298-024-00067-9
- Citations
- 5
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.95
Funders
- Québec Consortium for Drug Discovery
- National Institutes of Health
- National Research Council Canada
- National Institute of Allergy and Infectious Diseases